Cardiol Therapeutics Inc reports results for the quarter ended in June - Earnings Summary

Cardiol Therapeutics

13/08/2024 02:38

* Cardiol Therapeutics Inc  CRDL.TO  reported a quarterly
adjusted
loss of 10 cents​​ per share for the quarter ended in June,
higher than the same quarter last year, when the company
reported EPS of -12 cents.  The lone analyst forecast for the
quarter was for a loss of 13 cents per share. 
    * Reported revenue was zero​; analysts expected zero. 
    * Cardiol Therapeutics Inc's reported EPS for the quarter
was a
loss of 10 cents​.
    * The company reported a quarterly loss of C$6.59 million.
    * Cardiol Therapeutics Inc shares had risen by 1.5% this
quarter and gained 151.8% so far this year.

FORECAST CHANGES
    * The mean earnings estimate of analysts had risen by
about 7.1%
in the last three months.​ 
    * In the last 30 days, there have been no earnings estimate
revisions by analysts covering the company.

RECOMMENDATIONS
    * The current average analyst rating on the shares is "buy"
and
the breakdown of recommendations is 2 "strong buy" or "buy," no
"hold" and no "sell" or "strong sell." 
    * The average consensus recommendation for the biotechnology
&
medical research peer group is also "buy"

Wall Street's median 12-month price target for Cardiol
Therapeutics Inc is C$9.75 
This summary was machine generated from LSEG data August 13 at
01:37 a.m. UTC. ​All figures in Canadian dollars unless
otherwise stated. (For questions concerning the data in this
report, contact Estimates.Support@lseg.com. For any other
questions or feedback, contact
RefinitivNewsSupport@thomsonreuters.com) QUARTER ENDING    ESTIMATE       ACTUAL         BEAT, MET,
                                                 MISSED
 Jun. 30 2024      -0.13          -0.10          Beat
 Mar. 31 2024      -0.13          -0.14          Missed
 Dec. 31 2023      -0.12          -0.12          Met
 Sep. 30 2023      -0.12          -0.09          Beat